Clinicopathologic significance of tumor microenvironment CD11c, and FOXP3 expression in diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy.
- Author:
Seul LEE
1
;
Dong Hyun KIM
;
Sung Yong OH
;
So Yeon KIM
;
Myeong Seok KOH
;
Ji Hyun LEE
;
Suee LEE
;
Sung Hyun KIM
;
Jong Young KWAK
;
Min Gyoung PAK
;
Mi Ha JU
;
Hyo Jin KIM
;
Jin Sook JEONG
Author Information
- Publication Type:Original Article
- Keywords: Lymphoma, large B-cell, diffuse; CD11c; FOXP3; Tumor microenvironment
- MeSH: B-Lymphocytes*; Coloring Agents; Cyclophosphamide*; Dendritic Cells; Disease-Free Survival; Drug Therapy, Combination*; Humans; Immunohistochemistry; Lymphocytes; Lymphoma; Lymphoma, B-Cell*; Lymphoma, Large B-Cell, Diffuse; Prednisone*; Rituximab*; Tumor Microenvironment*; Vincristine*
- From:The Korean Journal of Internal Medicine 2017;32(2):335-344
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: CD11c is a dendritic cell marker in humans, which potentially induces a cytotoxic effect on lymphoma cells. Forkhead boxP3 (FOXP3) is a regulator of T lymphocyte in the microenvironment of the lymphoma. The principal objective of this study was to determine whether the tumors' microenvironment expressions of CD11c and FOXP3 are predictive of clinical outcomes in diffuse large B-cell lymphoma (DLBCL) patients receiving treatment with rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy. METHODS: The study population consisted of 100 patients with DLBCL. The CD11c and FOXP3 expression in primary tumors' microenvironment were evaluated using an immunohistochemistry (IHC). RESULTS: CD11c and FOXP3 expression positivity in microenvironment were 25% and 35%, respectively. Each one counted for 1 point. In CD11c and FOXP3 stain, positive was counted as 0 and negative was 1. The points were separated into low risk (0 to 1) and high risk (2) groups. Only the extranodal DLBCL patient group analysis conveyed significant differences of progression-free survival (p = 0.019) and overall survival (p = 0.039) between the two groups. CONCLUSIONS: We can achieve possible clinical significance of lymphoma tumor microenvironments through CD11c and FOXP3 IHC stains in extranodal DLBCL patients receiving R-CHOP therapy.
